Novel Antisense Drug Shows Promise in Slowing Fatty Liver Disease
A first-in-class clinical trial suggests a novel treatment measurably slowed progression of non-alcoholic fatty liver disease to its more progressive and deadly form.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.